Senior Manager Biostatistics, Clinical Trials
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Senior Manager Biostatistics, Clinical Trials to join our Global Development team, supporting our thrombosis therapeutic area in a hybrid work mode. In this role, you will provide statistical leadership across clinical development programs while collaborating with cross-functional development teams.
Job description
Discover your role
- Design and analyze clinical trials with Medical Directors, Clinical Scientists, and cross-functional partners.
- Develop clinical study protocols, statistical analysis plans, and statistical methodologies.
- Collaborate with Statistical Programming on tables, figures, and listings for regulatory reporting.
- Analyze clinical and non-trial data to support program-level decisions.
- Prepare reports, presentations, and regulatory communications, including agency meeting support.
- Lead research on innovative statistical methods and clinical trial applications.
- Mentor statisticians, oversee junior team members, and support contract staff management.
- You thrive in a collaborative environment and influence scientific decision-making.
This role requires
- PhD in Statistics/Biostatistics with 4+ years of pharmaceutical industry experience, or MS with 8+ years.
- Strong knowledge of drug discovery, drug development, and clinical trial strategy.
- Solid expertise in statistical analysis methodologies, experimental design, and clinical trial design.
- Proficiency with statistical software such as R or SAS.
- Ability to assess endpoints, evaluate analytical tools, and apply novel statistical methods.
- Experience interpreting data and communicating results to project teams, management, and regulatory agencies.
- Demonstrated leadership, influence, and collaboration skills in cross-functional settings.
- Strong critical thinking, time management, and communication skills in a fast-paced environment.
Requirements
- PhD in Statistics/Biostatistics with 4+ years of pharmaceutical industry experience, or MS with 8+ years
- Strong knowledge of drug discovery, drug development, and clinical trial strategy
- Solid expertise in statistical analysis methodologies, experimental design, and clinical trial design
- Proficiency with statistical software such as R or SAS
- Ability to assess endpoints, evaluate analytical tools, and apply novel statistical methods
- Experience interpreting data and communicating results to project teams, management, and regulatory agencies
- Demonstrated leadership, influence, and collaboration skills in cross-functional settings
- Strong critical thinking, time management, and communication skills in a fast-paced environment
Benefits
- Annual Bonuses
- Incentive Plans
- Equity Awards
- Pension or Retirement Benefits
- 401(k) Company Match
- Health and Wellness Programs
- Fitness Centers
- Medical, Dental & Vision
- Paid Time Off
- Family Support Benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.